IND-enabling study for TT-02332
Latest Information Update: 04 Mar 2024
At a glance
- Drugs TT 02332 (Primary)
- Indications Atherosclerosis; Dermatitis; Inflammatory bowel diseases; Neurodegenerative disorders; Non-alcoholic steatohepatitis; Obesity
- Focus Adverse reactions
Most Recent Events
- 04 Mar 2024 New trial record